Saturday, November 7, 2026

USD/CHF Jumps By 2% In The Last 21 Sessions

USD/CHF Jumps By 2% In The Last 21 Sessions

(VIANEWS) - USD/CHF (USDCHF) has been up by 2.17% for the last 21 sessions. At 21:06 EST on Wednesday, 3 April, USD/CHF (USDCHF) is $0.90.

USD/CHF's yearly highs and lows, it's 8.379% up from its 52-week low and 2.326% down from its 52-week high.

Volatility

USD/CHF's last week, last month's, and last quarter's current intraday variation average was 0.06%, 0.13%, and 0.30%, respectively.

USD/CHF's highest amplitude of average volatility was 0.31% (last week), 0.29% (last month), and 0.30% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CHF's Forex is considered to be oversold (<=20).

Previous days news about USD/CHF (USDCHF)

  • Usd/chf rises to near 0.9080 amid subdued real retail sales from Switzerland. According to FXStreet on Tuesday, 2 April, "The US Dollar (USD) received a boost as US Treasury bond yields surged following positive ISM Manufacturing PMI data from the United States (US), thereby supporting the USD/CHF pair."
  • Usd/chf remains below 0.9100 amid risk-off, bulls have the upper hand near YTD top. According to FXStreet on Wednesday, 3 April, "This, in turn, favours the US Dollar (USD) bulls and validates the positive outlook for the USD/CHF pair.", "The USD/CHF pair enters a bullish consolidation phase during the Asian session on Wednesday and oscillates in a narrow band near its highest level since November 11 touched the previous day. "

More news about USD/CHF (USDCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com